Werewolf Therapeutics, Inc. is a biopharmaceutical company engaged in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging its PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. The Company’s advanced clinical-stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and IL-12 INDUKINE molecules for the treatment of solid tumors. It is advancing WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor. It is advancing WTX-712, WTX-518, and WTX-921 through preclinical development.

Events Timeline

(ET)

2026-02-24

19:40:00

Werewolf Therapeutics Explores Strategic Alternatives to Enhance Shareholder Value

2026-02-13 (ET)

2026-02-13

16:30:00

Werewolf Therapeutics Cuts 64% Workforce, Expects $4.1M One-Time Charge

2025-12-18 (ET)

2025-12-18

08:20:00

Werewolf Therapeutics Updates on INDUKINE Programs

News

5.0

02-13stocktwits

Werewolf Therapeutics Cuts Workforce by 64% to Reduce Costs

2.0

02-13Yahoo Finance

Werewolf Therapeutics Board Approves Key Decision

2.0

01-05NASDAQ.COM

GH Research (GHRS) Stock Surges 22.36% Ahead of Key Update

3.5

2025-12-18Globenewswire

Werewolf Reports 30% Response Rate for WTX-124 Monotherapy in Melanoma Patients

2.0

2025-12-03NASDAQ.COM

Biotech Stocks Rise After Hours: Clene Jumps Ahead of ALS Update; Werewolf, Biomea, and Dyne Also Gain

2.0

2025-11-28NASDAQ.COM

Biotech Stocks MODD, LAB, HOWL, COGT, LGVN, and ABCL Surge in After-Hours Trading - Nov 26

4 Analyst Rating

Wall Street analysts forecast HOWL stock price to rise

2 Buy

2 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

1.00

Averages

4.00

High

7.00

Current: 0.000

Low

1.00

Averages

4.00

High

7.00

H.C. Wainwright

Andres Maldonado

Buy

downgrade

$10 -> $4

AI Analysis

2025-12-19

Reason

H.C. Wainwright

Andres Maldonado

Price Target

$10 -> $4

AI Analysis

2025-12-19

downgrade

Buy

Reason

H.C. Wainwright analyst Andres Maldonado lowered the firm's price target on Werewolf Therapeutics to $4 from $10 and keeps a Buy rating on the shares after the company announced a pipeline and business update. While the shares traded down on the news, the update "underscores tangible progress" toward Werewolf's primary value driver, the "creation of safer, systemically deliverable therapies," the analyst tells investors in a research note.

Wedbush

Outperform -> Neutral

downgrade

$3 -> $1

2025-12-19

Reason

Wedbush

Price Target

$3 -> $1

2025-12-19

downgrade

Outperform -> Neutral

Reason

Wedbush downgraded Werewolf Therapeutics to Neutral from Outperform with a price target of $1, down from $3.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for HOWL

Unlock Now

Valuation Metrics

The current forward P/E ratio for Werewolf Therapeutics Inc (HOWL.O) is -0.49, compared to its 5-year average forward P/E of -3.01. For a more detailed relative valuation and DCF analysis to assess Werewolf Therapeutics Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.01

Current PE

-0.49

Overvalued PE

0.03

Undervalued PE

-6.05

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.89

Current EV/EBITDA

-0.04

Overvalued EV/EBITDA

1.51

Undervalued EV/EBITDA

-3.30

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

21.30

Current PS

0.00

Overvalued PS

47.14

Undervalued PS

-4.53

Financials

AI Analysis

Annual

Quarterly

Whales Holding HOWL

Trading Trends

People Also Watch

Frequently Asked Questions

What is Werewolf Therapeutics Inc (HOWL) stock price today?

The current price of HOWL is 0.58345 USD — it has decreased -2.83

What is Werewolf Therapeutics Inc (HOWL)'s business?

What is the price predicton of HOWL Stock?

Wall Street analysts forecast HOWL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HOWL is4.00 USD with a low forecast of 1.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Werewolf Therapeutics Inc (HOWL)'s revenue for the last quarter?

Werewolf Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased

What is Werewolf Therapeutics Inc (HOWL)'s earnings per share (EPS) for the last quarter?

Werewolf Therapeutics Inc. EPS for the last quarter amounts to -0.36 USD, decreased -5.26

How many employees does Werewolf Therapeutics Inc (HOWL). have?

Werewolf Therapeutics Inc (HOWL) has 46 emplpoyees as of March 02 2026.

What is Werewolf Therapeutics Inc (HOWL) market cap?

Today HOWL has the market capitalization of 29.13M USD.

HOWL Overview

HOWL Overview

Events Timeline

News

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Whales Holding HOWL

Trading Trends

People Also Watch

Frequently Asked Questions

What is Werewolf Therapeutics Inc (HOWL) stock price today?

What is Werewolf Therapeutics Inc (HOWL)'s business?

What is the price predicton of HOWL Stock?

What is Werewolf Therapeutics Inc (HOWL)'s revenue for the last quarter?

What is Werewolf Therapeutics Inc (HOWL)'s earnings per share (EPS) for the last quarter?

How many employees does Werewolf Therapeutics Inc (HOWL). have?

What is Werewolf Therapeutics Inc (HOWL) market cap?